Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-22-036085

Chief Commercial Officer bought 28,200 shares at $0.71 ($20,022)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hanley Jr. Michael Conick Chief Commercial Officer 2022-06-08 Purchase +28,200 $0.71 $20,022 36,200 D: show line 1 in the form
Open-market purchases · 28,200 sh · avg $0.71 · $20,022
Loading xslF345X03/doc4.xml…